[{"orgOrder":0,"company":"Biosplice","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Cirtuvivint","moa":"CLK\/DYRK","graph1":"Oncology","graph2":"Phase I","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosplice \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Biosplice \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Biosplice","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cirtuvivint","moa":"CLK\/DYRK","graph1":"Oncology","graph2":"Phase I","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biosplice \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biosplice \/ Inapplicable"},{"orgOrder":0,"company":"Biosplice","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cirtuvivint","moa":"||CLK\/DYRK","graph1":"Oncology","graph2":"Phase I","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biosplice \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biosplice \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Cirtuvivint

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Interphex
Not Confirmed
Interphex
Not Confirmed

Details : The collaboration aims for Biosplice to expand its clinical candidate, SM08502 (cirtuvivint), as a standalone treatment and combination therapy in patients with AML and MDS.

Product Name : SM08502

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

December 09, 2024

Lead Product(s) : Cirtuvivint

Therapeutic Area : Oncology

Highest Development Status : Phase I

Sponsor : The Division of Cancer Treatment and Diagnosis

Deal Size : Undisclosed

Deal Type : Collaboration

blank

02

Interphex
Not Confirmed
Interphex
Not Confirmed

Details : Cirtuvivint (SM08502) is a small-molecule inhibitor of the CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation-regulated (DYRK) kinases that are emerging as key contributors to numerous forms of cancer.

Product Name : SM08502

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 09, 2022

Lead Product(s) : Cirtuvivint

Therapeutic Area : Oncology

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

03

Interphex
Not Confirmed
Interphex
Not Confirmed

Details : Cirtuvivint is a small-molecule inhibitor of the CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation-regulated (DYRK) kinases that are emerging as key contributors to numerous forms of cancer.

Product Name : SM08502

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 17, 2021

Lead Product(s) : Cirtuvivint,Abiraterone Acetate

Therapeutic Area : Oncology

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank